Table 1.

PFS outcomes from first-line, phase III dose-dense chemotherapy trials [28–31]

Trial	PFS (months)
	3-weekly carboplatin and 3-weekly paclitaxel	3-weekly carboplatin and weekly paclitaxel	Weekly carboplatin and weekly paclitaxel
JGOG3016	17.5	28.2 (HR 0.76, 95% CI 0.62–0.91, p = 0.0037)	N/A
MITO-7	17.3	N/A	18.3 (HR 0.96, 95% CI 0.80–1.16, p = 0.66)
ICON 8	17.7	20.8 (p = 0.35)	21.0 (p = 0.51)
GOG 262 + 3-weekly bevacizumab	14.0	14.7 (HR 0.89, 95% CI 0.74–1.06, p = 0.18)	N/A

The initial JGOG trial showed an advantage to dose dense chemotherapy but this was not confirmed in subsequent randomised trials (MITO-7, ICON8 and GOG 262). In addition, currently ongoing is the ICON 8B trial which is comparing weekly chemotherapy regimens with 3-weekly regimens, with concurrent bevacizumab (7.5 mg/kg) 3-weekly for a maximum of 22 cycles. The primary outcomes of ICON8B are PFS and OS